The Food and Drug Administration has granted approval to a drug called Aduhelm, developed by Biogen, for patients with Alzheimer's disease. The decision comes despite warnings from independent advisers that there isn't strong enough evidence to prove the treatment is effective in slowing the disease.
Read more here.
